Literature DB >> 18585397

Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.

Yukihiro Ohno1, Saki Shimizu, Junta Imaki, Shizuka Ishihara, Nobumasa Sofue, Masashi Sasa, Yoshiko Kawai.   

Abstract

We studied the effects of the 5-HT(1A/7) agonist 8-OH-DPAT on haloperidol-induced catalepsy and forebrain Fos expression in mice to clarify its mechanism in modulating extrapyramidal motor disorders. 8-OH-DPAT (0.1-1mg/kg, i.p.) markedly attenuated haloperidol-induced catalepsy in a dose-dependent manner with a potency greater than that of the antiparkinsonian agent trihexyphenidyl. The anticataleptic action of 8-OH-DPAT was completely antagonized by WAY-100135 (a selective 5-HT(1A) antagonist), but not by SB-269970 (a selective 5-HT(7) antagonist). Depletion of cerebral 5-HT by p-chlorophenylalanine (300mg/kg, i.p. for 3 days) did not attenuate, but rather potentiated the action of 8-OH-DPAT. Furthermore, the anticataleptic dose of 8-OH-DPAT showed a regionally specific reduction of haloperidol-induced Fos expression in the dorsolateral striatum (dlST) and the core region of the nucleus accumbens (AcC), without affecting that in the medial prefrontal cortex, the shell region of the nucleus accumbens or the lateral septal nucleus. These results suggest that 8-OH-DPAT alleviates antipsychotic-associated extrapyramidal motor disorders by stimulating the postsynaptic 5-HT(1A) receptors, which specifically counteracts the D(2) receptor blocking actions of antipsychotics in the dlST and AcC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585397     DOI: 10.1016/j.neuropharm.2008.06.005

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  11 in total

Review 1.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

Review 2.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

3.  Mechanism Underlying Organophosphate Paraoxon-Induced Kinetic Tremor.

Authors:  Higor Alves Iha; Naofumi Kunisawa; Saki Shimizu; Misaki Onishi; Yuji Nomura; Nami Matsubara; Chihiro Iwai; Mizuki Ogawa; Mai Hashimura; Kazuaki Sato; Masaki Kato; Yukihiro Ohno
Journal:  Neurotox Res       Date:  2019-02-07       Impact factor: 3.911

4.  Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain.

Authors:  Jérôme Maheux; Laura Vuillier; Mylène Mahfouz; Claude Rouillard; Daniel Lévesque
Journal:  Int J Neuropsychopharmacol       Date:  2011-04-28       Impact factor: 5.176

5.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

6.  Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine.

Authors:  Brian C Nolan; Shinban Liu; Lindsey R Hammerslag; Timothy H C Cheung; Jeffrey Lenz; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  Synapse       Date:  2013-07-17       Impact factor: 2.562

7.  Nicotine Elicits Convulsive Seizures by Activating Amygdalar Neurons.

Authors:  Higor A Iha; Naofumi Kunisawa; Saki Shimizu; Kentaro Tokudome; Takahiro Mukai; Masato Kinboshi; Akio Ikeda; Hidefumi Ito; Tadao Serikawa; Yukihiro Ohno
Journal:  Front Pharmacol       Date:  2017-02-09       Impact factor: 5.810

Review 8.  Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects.

Authors:  Yukihiro Ohno; Naofumi Kunisawa; Saki Shimizu
Journal:  Front Pharmacol       Date:  2019-09-17       Impact factor: 5.810

9.  Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.

Authors:  Kentaro Tokudome; Takahiro Okumura; Saki Shimizu; Tomoji Mashimo; Akiko Takizawa; Tadao Serikawa; Ryo Terada; Shizuka Ishihara; Naofumi Kunisawa; Masashi Sasa; Yukihiro Ohno
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

10.  Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway.

Authors:  Saki Shimizu; Shunsaku Sogabe; Ryoto Yanagisako; Akiyoshi Inada; Megumi Yamanaka; Higor A Iha; Yukihiro Ohno
Journal:  Int J Mol Sci       Date:  2017-07-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.